• 한국유가공학회:학술대회논문집
• /
• 2005.06a
• /
• pp.37-61
• /
• 2005

Microcapsules consisting of natural, biodegradable polymers for controlled and/or sustained core release applications are needed. Physicochemical properties of whey proteins suggest that they may be suitable wall materials in developing such microcapsules. The objectives of the research were to develop water-insoluble, whey protein-based microcapsules containing a model water-soluble drug using a chemical cross-linking agent, glutaraldehyde, and to investigate core release from these capsules at simulated physiological conditions. A model water soluble drug, theophylline, was suspended in whey protein isolate (WPI) solution. The suspension was dispersed in a mixture of dichloromethane and hexane containing 1% biomedical polyurethane. Protein matrices were cross-linked with 7.5-30 ml of glutaraldehyde-saturated toluene (GAST) for 1-3 hr. Microcapsules were harvested, washed, dried and analyzed for core retention, microstructure, and core release in enzyme-free simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) at 37$^{\circ}C$, A method consisting of double emulsification and heat gelation was also developed to prepare water-insoluble, whey protein-based microcapsules containing anhydrous milkfat (AMF) as a model apolar core. AMF was emulsified into WPI solution (15-30%, pH 4.5-7.2) at a proportion of 25-50% (w/w, on dry basis). The oil-in-water emulsion was then added and dispersed into corn oil (50 $^{\circ}C$)to form an O/W/O double emulsion and then heated at 85$^{\circ}C$ for 20 min for gelation of whey protein wall matrix. Effects of emulsion composition and pH on core retention, microstructure, and water-solubility of microcapsules were determined. Overall results suggest that whey proteins can be used in developing microcapsules for controlled and sustained core release applications.

• Macromolecular Research
• /
• v.17 no.12
• /
• pp.1039-1042
• /
• 2009

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• v.42 no.6
• /
• pp.393-393
• /
• 2016

• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.301.2-302
• /
• 2001

• Proceedings of the PSK Conference
• /
• 2003.04a
• /
• pp.299.1-299.1
• /
• 2003

Multivesicular DepoFoam technology is best suited for the encapsulation and sustained release of water-soluble drugs. The purpose of the present study was to prepare multivesicular DepoFoam particles and investigated possibility of oral delivery of a peptide, human epidermal growth factor (rhEGF). The multivesicular DepoFoam particles containing rhEGF was prepared by a two step water-in-oil-in-water double emulsification process. (omitted)

• Proceedings of the PSK Conference
• /
• 2003.10b
• /
• pp.227.2-228
• /
• 2003

In many biodegradable polymers recently investigated, poly(lactic acid)(PLA) or poly(lactic-co-glycolic acid)(PLGA) have extensively been utilized as drug delivery systems for sustained release drug delivery. Recently, there has been increased interest in electrospinning, which can produce fibers that are sub-micron in diameter. This technique has been applied to various micro/nano fabrication areas using numerous polymers but very few uses in the sharmaceutical area have been reported. (omitted)

• Journal of Pharmaceutical Investigation
• /
• v.29 no.1
• /
• pp.7-12
• /
• 1999

The captopril matrix tablets composed of polyethylene oxide(PEO) was prepared and administered to beagle dogs. Captopril matrix tablets were prepared using direct compressed method and wet granulation compressed method with various ratios of drug to PEO. The diffusion rate of captopril matrix tablets followed on the Higuchi's diffusion model. With increasing hardness of captopril matrix tablets, release rate was decreased. Each formulation was evaluated by the area under the curve (AUC) and time course of plasma captopril concentration after oral administration to beagle dogs. The $AUC_{0-12}$ were $9.126\;{\mu}g\;h/ml$ and $6.417\;{\mu}g\;h/ml$ for the matrix tablets and conventional tablets, respectively. Therefore, the bioavailability of captopril matrix tablets was greater than that of commercial product. It is suggested that captopril matrix tablets using PEO is a useful sustained release formulation.

• Journal of Pharmaceutical Investigation
• /
• v.18 no.1
• /
• pp.23-30
• /
• 1988

The sustained-release micropellets containing rifampicin were prepared by spray congealing micropelleting technique using gelatin as the embedding matrix, and hardened by treating with the formalin-isopropanol mixture. Dissolution of rifampicin from micropellets was significantly retarded, and greatly dependent on formalin concentration, hardening time and pH of the dissolution medium. It was found that this prolongation was more distinguished in pH 1.2 dissolution medium rather than pH 7.4, which might be attributed to the swelling characteristics of gelatin used in the dissolution medium. In-vitro dissolution kinetics indicated that the drug release followed the first-order process.

• Textile Coloration and Finishing
• /
• v.9 no.5
• /
• pp.52-62
• /
• 1997

Abstract Polyurethanes have been designed and fabricated into membranes with unique separation properties. Moreover, polyurethane microcapsules also have been reported actively as controlled release materials for their excellent blood compatibility, tensile strength and permeability. In this study, polyurethane microcapsules were synthesized by interfacial polymerization in an aqueous poly(ethylene glycol) dispersion of toluene diisocyanate in perfume oil using poly(vinyl alcohol) as the stabilizing agent. The effect of a few important process conditions on the average particle size and distributions, morphologies, and thermal properties to design microcapsules for the sustained release system was investigated.

• Macromolecular Research
• /
• v.17 no.7
• /
• pp.464-468
• /
• 2009

Gelatin nanoparticles derived from bovine or porcine have been developed as various types of drug delivery system, and they need to be cross-linked to maintain their physicochemical properties in aqueous environments. Although gelatin is a widely used material in pharmaceutical industries, the safety issue of animal-origin gelatins, such as transmissible mad cow disease and anaphylaxis, remains to be solved. The purpose of this study was to prepare type A gelatin (GA) nanoparticles by modified, two-step, desolvation method and compare the toxicity of the resulting GA nanoparticles with recombinant human gelatin (rHG) nanoparticles. The GA nanoparticles were characterized, and drug loading and release pattern were measured. FITC-BSA, a model protein, was efficiently loaded in the nanoparticles and then released in a biphasic and sustained release pattern without an initial burst. In particular, the cell viability of the GA nanoparticles was less than that of the rHG nanoparticles. This finding suggests that rHG nanoparticles should be considered as an alternative to animal-origin gelatin nanoparticles in order to minimize the safety problems.